Status:
COMPLETED
Rhopressa for Corneal Edema Associated With Fuchs Dystrophy
Lead Sponsor:
Price Vision Group
Conditions:
Fuchs Endothelial Dystrophy
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
The study objective is to determine whether use of Rhopressa improves the ability of corneal endothelial cells to maintain appropriate corneal hydration in patients with Fuchs endothelial corneal dyst...
Eligibility Criteria
Inclusion
- At least 18 years of age
- Male or female patient diagnosed with FECD and corneal edema evident by slit lamp exam and/or corneal tomography.
- Patient is able and willing to administer eye drops.
- Patient is able to comprehend and has signed the Informed Consent form.
Exclusion
- Active intraocular inflammation, corneal ulceration, keratitis, or conjunctivitis.
- Known sensitivity to any of the ingredients in the study medications.
- Abnormal eyelid function.
- History of herpetic keratitis.
- History of non-compliance with using prescribed medication.
- Current or planned pregnancy within the study duration.
- Concurrent involvement or participation in another randomized clinical trial within 30 days prior to enrollment in this study.
- Any ocular or systemic condition (i.e., UNCONTROLLED systemic disease) or situation which in the investigator's opinion may put the patient at significant risk, confound the study results, or interfere significantly with the patient's participation in the study.
Key Trial Info
Start Date :
August 5 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2020
Estimated Enrollment :
29 Patients enrolled
Trial Details
Trial ID
NCT04051463
Start Date
August 5 2019
End Date
July 1 2020
Last Update
October 19 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Price Vision Group
Indianapolis, Indiana, United States, 46260